These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22220592)

  • 1. Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.
    Congreve M; Andrews SP; Doré AS; Hollenstein K; Hurrell E; Langmead CJ; Mason JS; Ng IW; Tehan B; Zhukov A; Weir M; Marshall FH
    J Med Chem; 2012 Mar; 55(5):1898-903. PubMed ID: 22220592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A
    Basu S; Barawkar DA; Thorat S; Shejul YD; Patel M; Naykodi M; Jain V; Salve Y; Prasad V; Chaudhary S; Ghosh I; Bhat G; Quraishi A; Patil H; Ansari S; Menon S; Unadkat V; Thakare R; Seervi MS; Meru AV; De S; Bhamidipati RK; Rouduri SR; Palle VP; Chug A; Mookhtiar KA
    J Med Chem; 2017 Jan; 60(2):681-694. PubMed ID: 28055204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Chen L; Zhang J; Petter RC
    J Med Chem; 2004 Aug; 47(17):4291-9. PubMed ID: 15294001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a New Series of Potent Adenosine A
    Yang Z; Li L; Zheng J; Ma H; Tian S; Li J; Zhang H; Zhen X; Zhang X
    ACS Chem Neurosci; 2016 Nov; 7(11):1575-1584. PubMed ID: 27569066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.
    Vu CB; Shields P; Peng B; Kumaravel G; Jin X; Phadke D; Wang J; Engber T; Ayyub E; Petter RC
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4835-8. PubMed ID: 15341934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.
    Vu CB; Pan D; Peng B; Kumaravel G; Smits G; Jin X; Phadke D; Engber T; Huang C; Reilly J; Tam S; Grant D; Hetu G; Petter RC
    J Med Chem; 2005 Mar; 48(6):2009-18. PubMed ID: 15771443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel adenosine A(2A) receptor antagonists by virtual screening.
    Langmead CJ; Andrews SP; Congreve M; Errey JC; Hurrell E; Marshall FH; Mason JS; Richardson CM; Robertson N; Zhukov A; Weir M
    J Med Chem; 2012 Mar; 55(5):1904-9. PubMed ID: 22250781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.
    Sams AG; Mikkelsen GK; Larsen M; Langgård M; Howells ME; Schrøder TJ; Brennum LT; Torup L; Jørgensen EB; Bundgaard C; Kreilgård M; Bang-Andersen B
    J Med Chem; 2011 Feb; 54(3):751-64. PubMed ID: 21210664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
    Shook BC; Rassnick S; Osborne MC; Davis S; Westover L; Boulet J; Hall D; Rupert KC; Heintzelman GR; Hansen K; Chakravarty D; Bullington JL; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Palmer D; Reyes M; Demarest K; Tang Y; Rhodes K; Jackson PF
    J Med Chem; 2010 Nov; 53(22):8104-15. PubMed ID: 20973483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.
    Zhou G; Aslanian R; Gallo G; Khan T; Kuang R; Purakkattle B; De Ruiz M; Stamford A; Ting P; Wu H; Wang H; Xiao D; Yu T; Zhang Y; Mullins D; Hodgson R
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1348-54. PubMed ID: 26781932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and development of 1,3,5-triazine-thiadiazole hybrids as potent adenosine A
    Masih A; Singh S; Agnihotri AK; Giri S; Shrivastava JK; Pandey N; Bhat HR; Singh UP
    Neurosci Lett; 2020 Sep; 735():135222. PubMed ID: 32619652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian effects of novel adenosine A(2A) receptor antagonists.
    Drabczyńska A; Zygmunt M; Sapa J; Filipek B; Müller CE; Kieć-Kononowicz K
    Arch Pharm (Weinheim); 2011 Jan; 344(1):20-7. PubMed ID: 21213348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, biological evaluation and molecular modelling studies of 1,3,7,8-tetrasubstituted xanthines as potent and selective A
    Rohilla S; Bansal R; Kachler S; Klotz KN
    Bioorg Chem; 2019 Jun; 87():601-612. PubMed ID: 30933785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of a new series of 1,2,4-triazolo[1,5-a]-1,3,5-triazines as human A(2A) adenosine receptor antagonists with improved water solubility.
    Federico S; Paoletta S; Cheong SL; Pastorin G; Cacciari B; Stragliotto S; Klotz KN; Siegel J; Gao ZG; Jacobson KA; Moro S; Spalluto G
    J Med Chem; 2011 Feb; 54(3):877-89. PubMed ID: 21214204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.
    Endo K; Deguchi K; Matsunaga H; Tomaya K; Yamada K
    Bioorg Med Chem; 2014 Jun; 22(12):3072-82. PubMed ID: 24815000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A covalent antagonist for the human adenosine A
    Yang X; Dong G; Michiels TJM; Lenselink EB; Heitman L; Louvel J; IJzerman AP
    Purinergic Signal; 2017 Jun; 13(2):191-201. PubMed ID: 27915383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and characterization of optimized adenosine A₂A/A₁ receptor antagonists for the treatment of Parkinson's disease.
    Shook BC; Rassnick S; Wallace N; Crooke J; Ault M; Chakravarty D; Barbay JK; Wang A; Powell MT; Leonard K; Alford V; Scannevin RH; Carroll K; Lampron L; Westover L; Lim HK; Russell R; Branum S; Wells KM; Damon S; Youells S; Li X; Beauchamp DA; Rhodes K; Jackson PF
    J Med Chem; 2012 Feb; 55(3):1402-17. PubMed ID: 22239465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 1,3,5-triazine as adenosine A
    Masih A; Agnihotri AK; Srivastava JK; Pandey N; Bhat HR; Singh UP
    J Biochem Mol Toxicol; 2021 Mar; 35(3):e22659. PubMed ID: 33156955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
    Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
    PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one, a novel adenosine receptor antagonist with A(2A)-mediated neuroprotective effects.
    Scatena A; Fornai F; Trincavelli ML; Taliani S; Daniele S; Pugliesi I; Cosconati S; Martini C; Da Settimo F
    ACS Chem Neurosci; 2011 Sep; 2(9):526-35. PubMed ID: 22860174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.